Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical ...

Type 1 diabetes is more prevalent in Finland than anywhere else in the world, affecting approximately 50,000 people. New ...

An international, multisite Phase III trial, co-led by a University of Cincinnati researcher, has found that a Parkinson's disease medication delivered through an infusion pump is safe and ...

Levodopa is most commonly administered orally, but this trial tested continuous, 24-hour levodopa delivery through a subcutaneous infusion pump. Nutritional Management of Parkinsons disease ...

Espay, A. J., et al. (2024). Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson’s disease with motor fluctuations (BouNDless): a phase 3 ...

A recent study conducted in Finland shows that automated insulin delivery pumps significantly improved quality of life and reduced diabetes-related complications. The quality-adjusted life expectancy ...